FDA는 특정한 돌연변이를 가진 폐암에 대한 암젠 약물을 승인합니다.

newsroom 5/29 '21 posted 뉴스 IT

•, 2021년 5월 28일 미국 식품의약국(FDA)이 KRAS G12C 변종 또는 전이성 폐암(소형 폐암)을 가진 성인 환자의 치료를 위해 LUMAKRAS™을 승인했다고 발표했습니다.

• "오늘 FDA가 비소세포 폐암의 가장 보편적인 바이오마커 중 하나인 KRAS G12C를 대상으로 한 치료법을 승인함으로써 이러한 돌연변이를 가지고 있는 많은 환자들에게 희망을 주고 보다 혁신적인 치료 옵션이 필요한 폐암 커뮤니티에 중요한 순간입니다."

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer [www.prnewswire.com]

This Just-Approved Amgen Drug Is the First to Hit a Hard Target in Cancer [www.barrons.com]

Amgen Wins Approval for Pathbreaking Lung Cancer Drug [www.wsj.com]

FDA approves Amgen drug for lung cancer with specific mutation [www.nbcnews.com]

Are you a robot? [www.bloomberg.com]

newest replies popular replies

Open Wiki - Feel free to edit it. -

5/29 '21 answered

?Today, May 28, 2021, the first anti-KRAS targeted treatment is approved by @FDAOncology, marking a landmark step in the fight against cancer https://t.co/P57xTRmAGn
— Paolo Tarantino (@PTarantinoMD) May 28, 2021

BREAKING: For decades, scientists struggled to find a medicine that could treat one of the most common cancer mutations. Amgen has won approval from U.S. health regulators for the first drug targeting the KRAS mutation, ⁦@joewalkerWSJ⁩ reports. https://t.co/QdmdA0uSdJ
— Jonathan Rockoff (@jonathanrockoff) May 28, 2021

A major advance in oncology arrives! Very impressive speed from discovery to approval! Bravo @Amgen @US_FDA! Patients are waiting!https://t.co/4s1U0NPrel
— John Maraganore (@JMaraganore) May 28, 2021

Great news !! Finally a new targeted therapy option for patients with KRAS G12C mutation #LCSM @kRasKickers Many thanks to all the patients who participated in the clinical trials.. https://t.co/fWhuYAeFym
— Vamsi Velcheti, MD (@VamsiVelcheti) May 28, 2021

I thought I would never see the day a targeted agent would be @US_FDA approved for KRAS mutated cancer. This is a “potential blockbuster” says the @WSJ https://t.co/k9EJhJ9iID
— Lucky Lara (@PrimoLaraMD) May 28, 2021

Big Pharma at it again: Amgen Wins Approval for Pathbreaking Lung Cancer Drug https://t.co/5b79kKqwFf
— David Harsanyi (@davidharsanyi) May 28, 2021

Amgen Wins Approval for Pathbreaking Lung Cancer Drughttps://t.co/x5PsLagMJB
— Junaid (@juneymb) May 28, 2021

For decades, scientists struggled to find a medicine that could treat one of the most common cancer mutations.

Amgen has won approval from U.S. health regulators for the first drug targeting the KRAS mutation. https://t.co/kAhKKHOwSr
— Anthony DeRosa ? (@Anthony) May 28, 2021

Amgen Wins Approval for Pathbreaking Lung Cancer Drug https://t.co/AimfJjB8Uv
— Austin Petersen ?? (@AP4Liberty) May 28, 2021

.@US_FDA approves @Amgen drug for #lungcancer with specific mutation (KRAS G12C)... Hope for other patients that also carry this mutation. ? ? ? #LCSM #pancsm #crcsm @letswinpc https://t.co/fFMqSs66VZ via @nbcnews
— Dr. Allyson Ocean (@drallysonocean) May 28, 2021

permanent link

Featured

Important Notice: Discontinuation of Our Wiki Service

Dear Valued Users,

We hope this message finds you well. We are writing to inform you of an important upcoming change to our services. After careful consideration and analysis, we have made the difficult decision to discontinue our wiki site, effective one month from 2024/04/30.

This was not an easy decision to make, as we understand the importance of the resources and community that have been built around our wiki. However, due to evolving market conditions and strategic realignments, we must redirect our resources and efforts towards other ventures that will allow us to serve you better in the future.

What This Means for You:

Access to Content: You will continue to have full access to all content on the wiki until the discontinuation date. We encourage you to save or migrate any content you wish to retain.
Final Date of Service: The wiki will become inaccessible starting 1st June 2024, after which all content will be permanently removed.

We are immensely grateful for the support and contributions of our user community throughout the years. The wiki is being retired, but our team will be back soon with new services and apps.

Thank you for being a part of our journey.

Warm regards,

editoy Inc.

Related

Featured